

REFERENCES

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. *J Allergy Clin Immunol* 2001;108(Suppl. 5):S147-S334.
2. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, *et al.* Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen). *Allergy* 2008;63:8-160.
3. Meltzer EO. Quality of life in adults and children with allergic rhinitis. *J Allergy Clin Immunol* 2001;108(Suppl 1):545-53.
4. Milgrom H, Bender B. Adverse effects of medications for rhinitis. *Ann Allergy Asthma Immunol* 1997;78:439-46.
5. Spector SL. Overview of comorbid associations of allergic rhinitis. *J Allergy Clin Immunol* 1997;99:773-80.
6. Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: A critical evaluation of the literature. *Pharmacoeconomics* 2004;22:345-61.
7. Mygind N, Nielsen LP, Hoffmann HJ, Shukla A, Blumberga G, Dahl R, *et al.* Mode of action of intranasal corticosteroids. *J Allergy Clin Immunol* 2001;108:S16-25.
8. Schoenwetter WF, Dupclay L, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. *Curr Med Res Opin* 2004;20:305-17.
9. Frieri M, Therattil J, Chavarria V, Cosachov J, Kumar NS, Wang SF, *et al.* Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 1998;81:431-7.
10. Pipkorn U, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. *N Engl J Med* 1987;316:1506-10.

11. Molgaard E, Thomsen SF, Lund T, Pedersen L, Nolte H, Backer V. Differences between allergic and nonallergic rhinitis in a large sample of adolescents and adults. *Allergy* 2007;62:1033-7.
12. Dykewicz MS, Fineman S. Executive Summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. *Ann Allergy Asthma Immunol* 1998;81:463-8.
13. Meltzer EO. The prevalence and medical and economic impact of allergic rhinitis in the United States. *J Allergy Clin Immunol* 1997;99:S805-28.
14. Bunnag C, Kongpatanakul S, Jareoncharsri P, Voraprayoon S, Supatchaipisit P. A survey of allergic diseases in university students of Bangkok, Thailand. *J Rhinol* 1997;4:90-3.
15. Boonyarittipong P, Tuchinda M, Balangura K, Visitsuntorn N, Vanaprapara N. Prevalences of allergic diseases in Thai children. *J Pediatr Soc Thailand* 1990;29:24-32.
16. Vichyanond P, Sunthornchart S, Singhirannusorn V, Ruan-grat S, Kaewsomboon S, Visitsuntorn N. Prevalence of asthma, allergic rhinitis and eczema among university students in Bangkok. *Respir Med* 2002;96:34-8.
17. Barnes K, Marsh D. The genetics and complexity of allergy and asthma. *Immunol Today* 1998;19:325-32.
18. Middleton E, Reed CE, Ellis EE, Adkinson NF, Yunginger JW, Busse WW. *Allergy: Principles and Practice, Vol II. 4th ed. St. Louis: Mosby-Year Book.* 1993:1137-71.
19. Edfors-Lubs M. Allergy in 7,000 twin pairs. *Acta Allergol* 1971;26:249-85.
20. von Mutius E, Weiland SK, Fritsch C, Duhme H, Keil U. Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany. *Lancet* 1998;351:862-6.
21. Katz KA, Pocock SJ, Strachan DP. Neonatal head circumference, neonatal weight, and risk of hayfever, asthma and eczema in a large cohort of adolescents from Sheffield, England. *Clin Exp Allergy* 2003;33:737-45.
22. Braback L, Hedberg A. Perinatal risk factors for atopic disease in conscripts. *Clin Exp Allergy* 1998;28:936-42.

23. Fleming DM, Crombie DL. Prevalence of asthma and hay fever in England and Wales. *Br Med J Clin Res Ed* 1987;294:279-83.
24. Hagy GW, Settiple GA. Risk factors for developing asthma and allergic rhinitis. A 7-year follow-up study of college students. *J Allergy Clin Immunol Today* 1976;58:330-6.
25. Savolainen J, Viander M, Koivikko A. IgE-, IgA- and IgG-antibody responses to carbohydrate and protein antigens of *Candida albicans* in asthmatic children. *Allergy* 1990;45:54-63.
26. Gergen PJ, Turkeltaub PC. The association of individual allergen reactivity with respiratory disease in a national sample: data from the second National Health and Nutrition Examination Survey, 1976-80 (NHANES II). *J Allergy Clin Immunol* 1992;90:579-88.
27. Frosh AC, Sandhu G, Joyce R, Strachan DP. Prevalence of rhinitis, pillow type and past and present ownership of furred pets. *Clin Exp Allergy* 1999;29:457-60.
28. Pope C, Bates DV, Raizenne ME. Health effects of particulate air pollution: time for reassessment. *Environ Health Perspect* 1995;103:472-80.
29. Weiland SK, Mundt KA, Ruckmann A, Keil U. Self-reported wheezing and allergic rhinitis in children and traffic-density on street of residence. *Ann Epidemiol* 1994;4:79-83.
30. Keles N, Ilicali C, Deger K. The effects of different levels of air pollution on atopy and symptoms of allergic rhinitis. *Am J Rhinol* 1999;13:185-90.
31. Leaderer BP, Belanger K, Triche E, Holford T, Gold DR, Kim Y, *et al.* Dust mite, cockroach, cat, and dog allergen concentrations in homes of asthmatic children in the northeastern United States: impact of socioeconomic factors and population density. *Environ Health Perspect* 2002;110:419-25.
32. Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. *Clin Exp Allergy* 2006;36:689-703.

33. Ciprandi G, Buscaglia S, Pesce G, Pronzato C, Ricca V, Parmiani S, *et al.* Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. *J Allergy Clin Immunol* 1995;96:971-9.
34. Kay AB. Allergy and allergic diseases. First of two parts. *N Engl J Med* 2001;344:30-7.
35. Kulig M, Bergmann R, Klettke U, Wahn V, Tacke U, Wahn U. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. *J Allergy Clin Immunol* 1999;103:1173-9.
36. Illi S, von Mutius E, Lau S, Niggemann B, Grüber C, Wahn U. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. *Lancet* 2006;368:763-70.
37. Pearlman DS. Pathophysiology of the inflammatory response. *J Allergy Clin Immunol* 1999;104:S132-7.
38. Canonica GW. Introduction to nasal and pulmonary allergy cascade. *Allergy* 2002;57:8-12.
39. Baroody FM, Ford S, Proud D. Relationship between histamine and physiologic changes during the early response to nasal antigen provocation. *J Appl Physiol* 1999;86:659-68.
40. Bachert C, Hauser U, Prem B, Rudack C, Ganzer U. Proinflammatory cytokines in allergic rhinitis. *Eur Arch Otorhinolaryngol* 1995;252:S44-9.
41. Wang D, Clement P, Smitz J, DeWaele M, Derde MP. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure. *Int Arch Allergy Immunol* 1995;106:278-85.
42. Pastorello EA, Riario-Sforza GG, Incorvaia C, Segala M, Fumagalli M, Gandini R. Comparison of rhinomanometry, symptom score, and inflammatory cell counts in assessing the nasal late-phase reaction to allergen challenge. *J Allergy Clin Immunol* 1994;93:85-92.
43. Linder A, Venge P, Deuschl H. Eosinophil cationic protein and myeloperoxidase in nasal secretion as markers of inflammation in allergic rhinitis. *Allergy* 1987;42:583-90.

44. Wachs M, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Observations on the pathogenesis of nasal priming. *J Allergy Clin Immunol* 1989;84:492-501.
45. Baroody FM, Ford S, Lichtenstein LM, Kagey-Sobotka A, Naclerio RM. Physiologic responses and histamine release after nasal antigen challenge. Effect of atropine. *Am J Respir Crit Care Med* 1994;149:1457-65.
46. Wagenmann M, Baroody FM, Desrosiers M, Hubbard WC, Ford S, Lichtenstein LM, *et al.* Unilateral nasal allergen challenge leads to bilateral release of prostaglandin D₂. *Clin Exp Allergy* 1996;26:371-8.
47. Baroody FM, Foster KA, Markaryan A, deTineo M, Naclerio RM. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. *Ann Allergy Asthma Immunol* 2008;100:194-9.
48. Baroody FM, Shenaq D, DeTineo M, Naclerio RM. Intranasal fluticasone furoate (FF) reduces eye symptoms after nasal allergen challenge (NAC). *J Allergy Clin Immunol* 2008;121:S151.
49. Baraniuk JN, Lundgren JD, Okayama M, Goff J, Mullol J, Merida M, *et al.* Substance P and neurokinin A in human nasal mucosa. *Am J Respir Cell Mol Biol* 1991 4:228-36.
50. Okamoto Y, Shirotori K, Kudo K, Ishikawa K, Ito E, Togawa K, *et al.* Cytokine expression after the topical administration of substance P to human nasal mucosa. The role of substance P in nasal allergy. *J Immunol* 1993 151:4391-8.
51. Skoner DP. Complications of allergic rhinitis. *J Allergy Clin Immunol* 2000;105:S605-S9.
52. Bachert C, Hormann K, Mosges R, Rasp G, Riechelmann H, Müller R, *et al.* An update on the diagnosis and treatment of sinusitis and nasal polyposis. *Allergy* 2003;58:176-91.
53. Rachelefsky GS. National guidelines needed to manage rhinitis and prevent complications. *Ann Allergy Asthma Immunol* 1999;82:296-305.
54. Braunstahl GJ, Fokkens W. Nasal involvement in allergic asthma. *Allergy* 2003;58:1235-43.

55. Bousquet J, Vignola AM, Demoly P. Links between rhinitis and asthma. *Allergy* 2003;58:691-706.
56. Togias A. Unique mechanistic features of allergic rhinitis. *J Allergy Clin Immunol* 2000;105:S599-S604.
57. Bousquet J, Van Cauwenberge P. A critical appraisal of 'evidence-based medicine' in allergy and asthma. *Allergy* 2004;59:12-20.
58. International Consensus Report on Diagnosis and Management of Rhinitis. International Rhinitis Management Working Group. *Allergy* 1994;49(19 Suppl):1-34.
59. Woodcock A, Forster L, Matthews E, Martin J, Letley L, Vickers M, *et al.* Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. *N Engl J Med* 2003;349:225-36.
60. Tripathi A, Patterson R. Impact of allergic rhinitis treatment on quality of life. *Pharmacoeconomics* 2001;19:891-9.
61. The Allergy Report. *The American Academy of Allergy, Asthma & Immunology*, 2000.
62. Naclerio RM. Allergic rhinitis. *N Engl J Med* 1991;325:860-9.
63. Nathan RA. Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. *Ann Allergy Asthma Immunol* 2003;90:182-91.
64. Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of 'one linked airway disease'. *Ann Allergy Asthma Immunol* 2000;84:85-7.
65. Storms WW. Minimal persistent inflammation, an emerging concept in the nature and treatment of allergic rhinitis: the possible role of leukotrienes. *Ann Allergy Asthma Immunol* 2003;91:131-40.
66. Corey JP, Houser SM, Ng BA. Nasal congestion: a review of its etiology, evaluation, and treatment. *Ear Nose Throat J* 2000;79:690-3.
67. Bousquet J, Demoly P, Michel FB. Specific immunotherapy in rhinitis and asthma. *Ann Allergy Asthma Immunol* 2001;1:38-42.
68. Malling H. Immunotherapy as an effective tool in allergy treatment. *Allergy* 1998;53:461-72.

69. Borchers A, Keen C, Gershwin M. Fatalities following allergen immunotherapy. *Clin Rev Allergy Immunol* 2004;27:147-58.
70. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. *Pulm Pharmacol Ther* 2002;15:35-50.
71. Leung DY, Bloom JW. Update on glucocorticoid action and resistance. *J Allergy Clin Immunol* 2003;111:3-22.
72. Umland SP, Nahrebne DK, Razac S, Beavis A, Pennline KJ, Egan RW, *et al.* The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferongamma production by cultured primary CD4+ T cells. *J Allergy Clin Immunol* 1997;100:511-19.
73. Ciprandi G, Tosca MA, Passalacqua G, Canonica GW. Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. *Ann Allergy Asthma Immunol* 2001;86:433-8.
74. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. *BMJ* 1998;317:1624-9.
75. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. *Ann Allergy Asthma Immunol* 2002;89:479-84.
76. Spangler DL, Abelson MB, Ober A, Gotnes PJ. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. *Clin Ther* 2003;25:2245-67.
77. Minshall E, Ghaffar O, Cameron L, O'Brien F, Quinn H, Rowe-Jones J, *et al.* Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. *Otolaryngol Head Neck Surg* 1998;118:648-54.
78. Rosenblut A, Bardin PG, Muller B, Faris MA, Wu WW, Caldwell MF, *et al.* Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. *Allergy* 2007;62:1071-7.

79. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, *et al.* Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. *Pediatrics* 2000;105:E22.
80. Mahadevia P, Shah S, Leibman C, Kleinman L, O'Dowd L. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: A conjoint analysis. *Ann Allergy Asthma Immunol* 2004;93:345-50.
81. Bachert C, El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. *Ann Allergy Asthma Immunol* 2002;89:292-7.
82. Meltzer EO, Bardelas J, Goldsobel A, Kaiser H. A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis. *Treat Respir Med* 2005;4:289-96.
83. Clement PA. Committee report on standardization of rhinomanometry. *Rhinology* 1984;22:151-5.
84. Schumacher MJ. Rhinomanometry. *J Allergy Clin Immunol* 1989;83:711-8.
85. Bunnag C, Jareoncharsri P, Dachpunpour P, Vitavasiri A. Nasal airway resistance in asymptomatic Thai population. *Siriraj Hosp Gaz* 1995;47:721-5.
86. Cole P. Biophysics of nasal airflow: a review. *Am J Rhinol* 2000;14:245-9.
87. Meltzer EO, Jalowayski AA, Orgel HA, Harris AG. Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray. *J Allergy Clin Immunol* 1998;102:39-49.
88. Flanagan P, Eccles R. Spontaneous changes of unilateral nasal airflow in man. A re-examination of the 'nasal cycle'. *Acta Otolaryngol* 1997;117:590-5.
89. Rundcrantz H. Posture and congestion of nasal mucosa allergic rhinitis. *Acta Otolaryngol* 1969;58:281-7.
90. Cole P, Forsyth R, Haight JS. Effects of cold air and exercise on nasal patency. *Ann Otol Rhinol Laryngol* 1983;92:196-8.

91. Meltzer EO, Orgel HA, Bronsky EA, Furukawa CT, Grossman J, LaForce CF, *et al.* A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. *J Allergy Clin Immunol* 1990;86:221-30
92. Howarth PH. The cellular basis for allergic rhinitis. *Allergy* 1995;50:6-10.
93. Fokkens WJ, Godthelp T, Holm AF, Blom H, Klein-Jan A. Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. *Allergy* 1997;52:29-32.
94. Harold S. Mechanisms of intranasal steroids in the management of upper respiratory allergic diseases. *J Allergy Clin Immunol* 1999;104:S138-43.
95. Lans DM, Alfano N, Rocklin R. Nasal eosinophilia in allergic and nonallergic rhinitis: usefulness of the nasal smear in the diagnosis of allergic rhinitis. *Allergy Proc* 1989 10:275-80.
96. Stephen JG. Mast cells and basophils. *Curr Opin Hematol* 2000; 7:32-9.
97. Rasp G, Hochstrasser K. Tryptase in nasal fluid is a useful marker of allergic rhinitis. *Allergy* 1993;48:72-4.
98. Naclerio RM, Proud D, Togias AG, Adkinson NF, Meyers DA, Kagey-Sobotka A, *et al.* Inflammatory mediators in late antigen induced rhinitis. *N Engl J Med* 1985;313:65-70.
99. Borres MP, Irander K, Björkstén B. Metachromatic cells in nasal mucosa after allergen challenge. *Allergy* 1990;45:98-103.
100. Connell JT. Nasal disease: mechanisms and classification. *Ann Allergy* 1983;50:227-35.
101. Pelikan Z, Pelikan-Filipek M. Cytologic changes in the nasal secretions during the late nasal response. *J Allergy Clin Immunol* 1989;83:1068-79.
102. Wilson NW, Jallowayski AA, Hamburger RN. A comparison of nasal cytology with sinus x-rays for the diagnosis of sinusitis. *Am J Rhinol* 1988;2:55-9.
103. Gordon S. *Macrophages and the Immune Response*, 4th ed., Chapter 15. Lippincott Raven: RI, USA. 1999:533-45.
104. Keshav S, Chung LP, Gordon S. Macrophage products in inflammation. *Diagn Microbiol Infect Dis* 1990;13:439-47.


105. Wilson K. Wound healing: the role of macrophages. *Nurs Crit Care* 1997;2:291-6.
106. Doherty TM. T-cell regulation of macrophage function. *Curr Opin Immunol* 1995;7:400-4.
107. Juliusson S, Bachert C, Klementsson H, Karlsson G, Pipkorn U. Macrophages on the nasal mucosal surface in provoked and naturally occurring allergic rhinitis. *Acta Otolaryngol Stockh* 1991;111:946-53.
108. Romagnani S. Regulation of the development of type 2 T-helper cells in allergy. *Curr Opin Immunol* 1994;6:838-46.
109. Lichtman AH, Abbas AK. T-cell subsets: recruiting the right kind of help. *Curr Biol* 1997;7:R242-4.
110. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. *Immunol Today* 1998;19:568-74.
111. Pawankar RU, Okuda M, Okubo K, Ra C. Lymphocyte subsets of the nasal mucosa in perennial allergic rhinitis. *Am J Respir Crit Care Med* 1995;152:2049-58.
112. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, *et al.* Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. *J Immunol Today* 1992;148:2390-4.
113. Durham SR, Gould HJ, Hamid QA. Local IgE production in nasal allergy. *Int Arch Allergy Immunol* 1997;113:128-30.
114. Salter M, Biggadike K, Matthews JL, West MR, Haase MV, Farrow SN, *et al.* Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. *Am J Physiol* 2007;293:L660-L7.
115. Valotis A, Hogger P. *Human receptor kinetics and tissue affinity of the enhanced affinity glucocorticoid fluticasone furoate (GW685698X).* XXV Congress of the European Academy of Allergology and Clinical Immunology, Vienna, Austria, June 10-14, 2006.

116. Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare?. *J Allergy Clin Immunol* 1999;104:S144-S9.
117. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. *Allergy* 2008;63:1292-300.
118. Nasonex [package insert]. Kenilworth, NJ: Schering Corporation, 2005.
119. Berkowitz RB, Roberson S, Zora J, Capano D, Chen R, Lutz C, *et al.* Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. *Allergy Asthma Proc* 1999;20:167-72.
120. Anolik R, Pearlman DS, Teper A, Gates D. Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents. *Allergy Asthma Proc* 2009;30:406-12.
121. Veramyst [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2007.
122. Hughes SC, Shardlow PC, Hollis FJ, Scott RJ, Motivaras DS, Allen A, *et al.* Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. *Drug Metab Dispos* 2008;36:2337-44.
123. Kaiser HB, Naclerio RM, Given J, Toler TN, Ellsworth A, Philpot EE. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. *J Allergy Clin Immunol* 2007;119:1430-7.
124. Vasar M, Houle PA, Douglass JA, Meltzer EO, Silvey M, Wu W, *et al.* Fluticasone furoate nasal spray: effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. *Allergy Asthma Proc* 2008;29:313-21.
125. Biggadike K, Bledsoe RK, Hassell AM, Kirk BE, McLay IM, Shewchuk LM, *et al.* X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. *J Med Chem* 2008;51:3349-52.
126. Zilstorff-Pedersen K. Quantitative measurements of the nasolacrimal reflex. *Arch Otolaryngol* 1965;81:457- 62.

127. Philip G, Baroody FM, Proud D, Naclerio RM, Togias AG. The human nasal response to capsaicin. *J Allergy Clin Immunol* 1994;94:1035-45.
128. Gilbert AN, Rosenwasser AM. Biological rhythmicity of nasal airway patency: a re-examination of the 'nasal cycle'. *Acta Otolaryngol* 1987;104:180-6.
129. Hasegawa M, Saito Y. Postural variations in nasal resistance and symptomatology in allergic rhinitis. *Acta Otolaryngol* 1979;88:268-72.
130. Miljeteig H, Haight JS, Cole P. Nasal resistance in recumbency and sleep. *Rhinology* 1995;33:82-3.
131. Wang DY, Clement P, Smitz J, De Waele M, Derde MP. Quantification of eosinophil cationic protein and eosinophils in nasal secretions of the allergen-induced nasal inflammation. *Allergol Immunopathol* 1994;22:179-83.
132. Nishioka K, Saito C, Nagano T, Okano M, Masuda Y, Kuryama T. Eosinophil cationic protein in nasal secretions of the patients with mite allergic rhinitis. *Laryngoscope* 1993;103:189-92.
133. Okuda M, Otsuka H. Basophilic cells in allergic nasal secretions. *Arch Otorhinolaryngol* 1977;214:283-9.
134. Lang DM, Howland WC, Stevenson DD. Sensitivity and features of nasal cytology in diagnosis of allergic (IgE mediated) rhinitis [abstract]. *Ann Allergy Asthma Immunol* 1988;60:176.
135. Amin K, Rinne J, Haahtela T, Simola M, Peterson CG, Roomans GM, *et al.* Inflammatory cell and epithelial characteristics of perennial allergic and nonallergic rhinitis with a symptom history of 1 to 3 years' duration. *J Allergy Clin Immunol* 2001;107:249-57.
136. Venge P. Eosinophil and neutrophil granulocytes. *Allergy* 1993;48:39-47.
137. Meltzer EO. Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. *Ann Allergy Asthma Immunol* 2007;98:12-21.
138. Berger W, Godfrey JW, Grant AC, Slater AL, Broughton SJ. Fluticasone furoate (FF) nasal spray: development of a next-generation delivery system for allergic rhinitis [abstract no. 907]. *J Allergy Clin Immunol* 2007;119:S231.

139. Rabago D, Zgierska A. Saline nasal irrigation for upper respiratory conditions.

Am Fam Physician 2009 80:1117-9.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่

Copyright© by Chiang Mai University
All rights reserved